TY - JOUR T1 - Once-daily indacaterol 150µg or 300µg and other bronchodilators in COPD patients of GOLD 2011 groups A and B JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P758 AU - H. Kerstjens AU - O. Kornmann AU - G. Deslée AU - D. Young AU - D. Lawrence AU - D. McBryan Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P758.abstract N2 - IntroductionIndacaterol (IND) is an inhaled, once-daily, 24 hr long-acting β2-agonist for the treatment of COPD. We report on the effectiveness of IND and other long-acting bronchodilators compared to placebo in patients of GOLD 2011 groups A and B.MethodsA post-hoc, subgroup pooled analysis of 6-month efficacy data from 3 randomized, placebo controlled studies (n=3862) was performed across GOLD groups A–D categorized according to FEV1 % predicted, mMRC dyspnea scale and exacerbation history in the 12 months prior to entry (yes/no). Once-daily IND 150µg or 300µg, open-label tiotropium (TIO) 18µg; twice-daily salmeterol (SAL) 50µg or formoterol (FOR) 12µg were compared to placebo. Endpoints included trough FEV1, TDI, and SGRQ total score, all at Week 26, and mean rescue medication use over 26 weeks.ResultsIn GOLD groups A and B, IND 150µg and 300µg significantly improved FEV1, TDI, SGRQ total score and mean rescue medication use compared with placebo.View this table:Adjusted mean treatment difference vs placeboConclusionTreatment selection according to patient’s symptoms as well as risk is an important consideration in the treatment of COPD as per GOLD. IND 150µg and 300µg effectively improved lung function, health status, and symptoms in GOLD 2011 group A and B patients. ER -